Inagaki Koichi, Hahn Harvey S, Dorn Gerald W, Mochly-Rosen Daria
Department of Molecular Pharmacology, Stanford University School of Medicine, Stanford, Calif 94305-5174, USA.
Circulation. 2003 Aug 19;108(7):869-75. doi: 10.1161/01.CIR.0000081943.93653.73. Epub 2003 Jul 14.
Protein kinase C (PKC) plays a major role in cardioprotection from ischemia/reperfusion injury. Using an HIV-1 Tat protein-derived peptide to mediate rapid and efficient transmembrane delivery of peptide regulators of PKC translocation and function, we examined the cardioprotective effect of selective delta-PKC inhibitor (deltaV1-1) and epsilon-PKC activator (psi(epsilon)RACK) peptides for ischemia/reperfusion damage in isolated perfused rat hearts. Furthermore, we examined the protective effects of these PKC isozymes in isolated perfused hearts subjected to ischemia/reperfusion damage using transgenic mice expressing these peptides specifically in their cardiomyocytes.
In isolated perfused rat hearts, administration of deltaV1-1 but not psi(epsilon)RACK during reperfusion improved cardiac function and decreased creatine phosphokinase release. In contrast, pretreatment with psi(epsilon)RACK but not deltaV1-1, followed by a 10-minute washout before ischemia/reperfusion, also improved cardiac function and decreased creatine phosphokinase release. Furthermore, administration of psi(epsilon)RACK before ischemia followed by deltaV1-1 during reperfusion only conferred greater cardioprotective effects than that obtained by each peptide treatment alone. Both the delta-PKC inhibitor and epsilon-PKC activator conferred cardioprotection against ischemia/reperfusion injury in transgenic mice expressing these peptides in the heart, and coexpression of both peptides conferred greater cardioprotective effects than that obtained by the expression of each peptide alone.
delta-PKC inhibitor prevents reperfusion injury, and epsilon-PKC activator mimics ischemic preconditioning. Furthermore, treatment with both peptides confers additive cardioprotective effects. Therefore, these peptides mediate cardioprotection by regulating ischemia/reperfusion damage at distinct time points.
蛋白激酶C(PKC)在心肌缺血/再灌注损伤的心脏保护中起主要作用。我们利用一种源自HIV-1 Tat蛋白的肽介导PKC易位和功能的肽调节剂的快速高效跨膜递送,研究了选择性δ-PKC抑制剂(δV1-1)和ε-PKC激活剂(ψ(ε)RACK)肽对离体灌注大鼠心脏缺血/再灌注损伤的心脏保护作用。此外,我们利用在心肌细胞中特异性表达这些肽的转基因小鼠,研究了这些PKC同工酶在离体灌注心脏缺血/再灌注损伤中的保护作用。
在离体灌注大鼠心脏中,再灌注期间给予δV1-1可改善心脏功能并减少肌酸磷酸激酶释放,而给予ψ(ε)RACK则无此作用。相反,在缺血/再灌注前用ψ(ε)RACK预处理(随后冲洗10分钟),也可改善心脏功能并减少肌酸磷酸激酶释放,而用δV1-1预处理则无此作用。此外,缺血前给予ψ(ε)RACK,再灌注期间给予δV1-1,其心脏保护作用比单独给予每种肽更强。δ-PKC抑制剂和ε-PKC激活剂均可对心脏中表达这些肽的转基因小鼠的缺血/再灌注损伤起到心脏保护作用,两种肽共同表达的心脏保护作用比单独表达每种肽更强。
δ-PKC抑制剂可预防再灌注损伤,ε-PKC激活剂可模拟缺血预处理。此外,两种肽联合治疗具有相加的心脏保护作用。因此,这些肽通过在不同时间点调节缺血/再灌注损伤来介导心脏保护作用。